Total pregnancy-associated plasma protein A - A first trimester maternal serum marker for Down's syndrome: Clinical and technical assessment of a poly-monoclonal enzyme immunoassay

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 63, Issue 6, 2003, Pages 407-416

  Christiansen, M ^a   Jaliashvili, I ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Eosinophil major basic protein; Pregnancy proteins; Pregnancy associated plasma protein A; Prenatal screening; Trisomy 21

Indexed keywords

BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; ENZYME ANTIBODY; HEPARIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTISERUM; PREGNANCY ASSOCIATED PLASMA PROTEIN A; THYROGLOBULIN;

ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOWN SYNDROME; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GEL FILTRATION; GESTATIONAL AGE; HUMAN; IMMUNOREACTIVITY; MASS SCREENING; MATERNAL SERUM; PREGNANCY; PRIORITY JOURNAL; SIMULATION;

MURINAE; ORYCTOLAGUS CUNICULUS;

EID: 0142062127     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510310002248     Document Type: Article

References (34)

1. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, Saller DN, Bowers GB. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1998; 3327: 588-93.
2. Forest JC, Masse J, Moutquin JM. Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Clin Biochem 1997; 30: 333-8.
3. Brambati B, Tului L, Shrimanker K, Suzuki Y, Grudzinskas JG. Serum PAPP-A and free b-HCG are first trimester screening markers for Down syndrome. Prenat Diagn 1994; 14: 1043-9.
4. Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-trimester Down syndrome screening: free β-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am J Obstet Gynecol 1996; 174: 612-6.
5. Wald NJ, George L, Smith D, Densem JW, Pettersson K. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynecol 1996; 103: 407-12.
6. Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters. Br J Obstet Gynaecol 1997; 104: 811-7.
7. Qin Q-P, Nguyen TH, Christiansen M, Larsen SO, Nørgaard-Pedersen B. Time-resolved immunofluorometric assay of pregnancy-associated plasma protein A in maternal serum screening for Down's syndrome in first trimester of pregnancy. Clin Chim Acta 1996; 254: 113-29.
8. Qin Q-P, Christiansen M, Oxvig C, Pettersson K, Sottrup-Jensen L, Koch C, Nørgaard-Pedersen B. Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome. Clin Chem 1997; 43: 2323-32.
9. Biagiotti R, Brizzi L, Periti E, d'Agata A, Vanzi E, Cariati E. First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal tranlucency thickness. Br J Obstet Gynaecol 1998; 105: 917-20.
10. Wald NJ, Watt HC, Hacksaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341: 461-7.
11. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. One-step clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002; 20: 219-25.
12. Wald NJ, Hacksaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997; 17: 821-9.
13. Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J Biol Chem 1993; 268: 12243-6.
14. Oxvig C, Sand O, Kristensen T, Kristensen L, Sottrup-Jensen L. Isolation and characterization of circulating complex between human pregnancy-associated plasma protein-A and proform of eosinophil major basic protein. Biochim Biophys Acta 1994; 71: 560-6.
15. Overgaard MT, Haaning J, Boldt HB, Olsen IM, Laursen LS, Christiansen M, Gleich GJ, Sottrup-Jensen L, Conover CA, Oxvig C. Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J Biol Chem 2000; 275: 31128-33.
16. Conover CA, Oxvig C. Overgaard MT, Christiansen M, Giudice L. Evidence that the insulin-like growth factor binding protein-4 protease in human follicular fluid is pregnancy associated plasma protein-A. J Clin Endocrinol Metab 1999; 84: 4742-5.
17. Oxvig C, Haaning J, Kristensen L, Wagner JM, Rubin I, Stigbrand T, Gleich GJ, Sottrup-Jensen L. Identification of angiotensinogen and complement C3dg as novel proteins binding proform of eosinophil major basic protein in human pregnancy serum and plasma. J Biol Chem 1995; 270: 13645-51.
18. Christiansen M, Nørgaard-Pedersen B. Maternal serum screening for Down's syndrome in first trimester using Schwangerschaftsprotein 1, PAPP-A/proMBP-complex and the proform of eosinophil major basic protein as markers. In: Grudzinskas JG, Chard T, editors. Screening for Down syndrome in first trimester. London: RCOG; 1997, pp. 148-62
19. Mowles EA, Pinto-Furtado LG, Bolton AE. A two-site immunoradiometric assay for human pregnancy-associated plasma protein-A (PAPP-A) using monoclonal antibodies. J Immunol Meth 1986; 95: 129-33.
20. Christiansen M, Jaliashvili I, Overgaard MT, Ensinger C, Obrist P, Oxvig C. Quantification and characterization of pregnancy-associated complexes of angiotensinogen and the proform of eosinophil major basic protein in serum and amniotic fluid. Clin Chem 2000; 46: 1099-5.
21. Cuckle HS, van Lith JM. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999; 19: 505-12.
22. Larsen SO, Christiansen M. Nørgaard-Pedersen B. Calculation of ROC curves in multidimensional likelihood ratio based screening procedures with screening for Down's syndrome as a special case. J Med Screen 1998; 5: 57-62.
23. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 387-402.
24. van der Veen WJ, Beekhuis JR, Cornel MC, Mantingh A, de Walle HE, de Wolf BT. A demographic approach to the assessment of Down syndrome screening. Prenat Diagn 1997; 17: 717-24.
25. Bersinger NA, Zakher A, Huber U, Pescia G, Schneider H. A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down's syndrome and other trisomies. Arch Gynecol Obstet 1995; 256: 185-92.
26. Bueler MR, Bersinger NA. Antiserum to pregnancy-associated plasma protein A (PAPP-A) recognises human haptoglobin. Br J Obstet Gynaecol 1989; 96: 867-9.
27. Bischof P, Haenggeli L, Sizonenko MT, Hermann W, Sizonenko PC. Radioimmunoassay for the measurement of pregnancy-associated plasma protein-A (PAPP-A). Biol Reprod 1981; 24: 1076-81.
28. Sinosich MJ, Teisner B, Folkerson J, Saunders DN, Grudzinskas JG. Radioimmunoassay for pregnancy-associated plasma protein A. Clin Chem 1982; 28: 50-3.
29. Christiansen M, Olesen Larsen S. An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat Diagn 2002; 22: 482-6.
30. Pettersson K, Alfthan H, Stenman UH, Turpeinen U, Suonpää M, Söderholm J, Larsen SO, Nørgaard-Pedersen B. Simultaneous assay of α-fetoprotein and free ß subunit of human chorionic gonadotrophin by dual label time-resolved immunofluorometric assay. Clin Chem 1993; 39: 2084-9.
31. Qin Q-P, Christiansen M, Lövgren T, Nørgaard-Pedersen B, Pettersson K. Dual-label time-resolved immunofluorometric assay for simultaneous determination of pregnancy-associated plasma protein A and free β-subunit of human chorionic gonadotrophin. J Immunol Meth 1997; 295: 169-75.
32. Christiansen M, Larsen S. Precision of risk in multidimensional likelihood ratio-based screening with first trimester screening for Down's syndrome as a special case. J Med Screen 2001; 8: 61-4.
33. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022-9.
34. Bayes-Genis A, Schwartz RS, Lewis DA, Overgaard MT, Christiansen M, Oxvig C, Ashai K, Holmes DR Jr, Conover CA. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vase Biol 2001; 21: 335-41.